KBC Securities - AB InBev

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

First Name*

Last Name*

Country*

Email*

Password* ( 6 or more alphabetic and numerical characters )

Get financial insights straight to your inbox

YES

I have read and accept ResearchPool Terms & Conditions, and Privacy Policy, including our Cookie Use Policy

Already on ResearchPool? Login Now

Report

KBC Securities

BC-Paul Rose

AB InBev

Enter Summary Here

25/08/2021 5 EN

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

BC-Paul Rose

Other Reports from KBC Securities

Guy Sips

Guy Sips

Biotalys Refocusing strategy on lead assets and cutting annual cash burn

We will update our model (from “Buy” to “under review”) after Biotalys plans a strategic refocus, concentrating resources on its top-priority biofungicide programs. Early-stage activities will be suspended and the organization downsized to cut costs while protecting long-term platform value. The shift prioritizes EVOCA NG, BioFun-6, and already partnered programs with the Gates Foundation and Syngenta. These measures aim to reduce cash burn by €20m through 2028 and strengthen commercialization readiness. Biotalys intends to cut 30 jobs (In 2025 Biotalys on average had 59 employees.), maintains...

5h / 20m 5h / 20m 1 EN

Hilde Van Boxstael ... (+4)

Hilde Van Boxstael
Kristof Samoy
Wim Hoste
Wim Lewi

Morning Notes : DSFIR NA, CMBT BB, GBLB BB, PROX BB, NXFIL NA

: DSFIR NA, CMBT BB, GBLB BB, PROX BB, NXFIL NA

9h / 15m 9h / 15m 1 EN

Wim Hoste

Wim Hoste

DSM-Firmenich FIRST LOOK: Sale of ANH to CVC for EV of up to € 2.2bn

Dsm-firmenich announced the divestment of its ANH business to CVC, while it will retain a 20% minority stake for now. The deal value (EV of up to € 2.2bn for 100%; implying a c. 7x EV/normalized adjusted EBITDA multiple) is in line with recent market rumours although below our € 3bn forecast, while also other elements in the deal structure are a bit disappointing (price tag included €0.5bn earn-out, a loan & liquidity facility will be provided). Despite the lower than expected ANH deal metrics, we welcome the ANH as it allows dsm-firmenich to turn the page on the long awaited strategic transfo...

9h / 26m 9h / 26m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

AB InBev

We are a financial services provider for several types of professional clients, each with distinct needs.

Biotalys Refocusing strategy on lead assets and cutting annual cash burn

Morning Notes : DSFIR NA, CMBT BB, GBLB BB, PROX BB, NXFIL NA

DSM-Firmenich FIRST LOOK: Sale of ANH to CVC for EV of up to € 2.2bn

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe